Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Blood (2023) 142 (Supplement 1): 299.

https://doi.org/10.1182/blood-2023-173615

Published: 2023

Journal Articles

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

Alexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Kirsten Grønbæk, Jan Sundberg, Lone Bredo Pedersen, Elisabeth Ralfkiær, Marja-Liisa Karjalainen-Lindsberg, Christer Sundström, Mats Ehinger, Christian Geisler, Mats Jerkeman

Blood (2016) 128 (14): 1814–1820.

https://doi.org/10.1182/blood-2016-03-704023

Published: 2016

Includes: Supplemental data

Journal Articles

Subset-Specific Spectra of Recurrent Gene Mutations in Chronic Lymphocytic Leukemia with Stereotyped B-Cell Receptors

Blood (2014) 124 (21): 3320.

https://doi.org/10.1182/blood.V124.21.3320.3320

Published: 2014

Journal Articles

Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results

Marinus H.J. van Oers, Kazimierz Kuliczkowski, MD PhD Prof., Lukas Smolej, Mario Petrini, Fritz Offner, Sebastian Gorsicki, Mark-David Levin, Ira Gupta, Jennifer Phillips, Vanessa Williams, Steen Lisby, Christian Geisler

Blood (2014) 124 (21): 21.

https://doi.org/10.1182/blood.V124.21.21.21

Published: 2014

Journal Articles

Increased Expression Levels Of SOX11 Correlates To Overall Survival and Adds Prognostic Value To The MIPI and MIPI-B Index In a Homogenously Treated Cohort

Lena Nordström, Venera Kuci, Sandra Sernbo, Kirsten Groenbaek, MD, DMSc, Arne Kolstad, Riika Räty, Marja-Liisa Karjalainen, Christian Geisler, Elisabeth Ralfkiaer, MD, DMSc, Christer Sundström, Anna Laurell, Jan Delabie, Mats Ehinger, Mats Jerkeman, Sara Ek

Blood (2013) 122 (21): 4272.

https://doi.org/10.1182/blood.V122.21.4272.4272

Published: 2013

Journal Articles

Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy For Patients >65 Years With Mantle Cell Lymphoma: Preliminary Results From The Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase I-II Trial

Mats Jerkeman, Alexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Kirsten Grønbæk, Jan Sundberg, Lone Bredo Pedersen, Christian Geisler

Blood (2013) 122 (21): 4377.

https://doi.org/10.1182/blood.V122.21.4377.4377

Published: 2013

Journal Articles

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

Blood (2012) 119 (19): 4467–4475.

https://doi.org/10.1182/blood-2011-11-393694

Published: 2012

Includes: Supplemental data

Journal Articles

Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases

Blood (2011) 118 (11): 3088–3095.

https://doi.org/10.1182/blood-2011-03-343434

Published: 2011

Includes: Supplemental data

Journal Articles

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Tadeusz Robak, MD, PhD, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Céligny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Christian Geisler, MD, DMSc, Marco Montillo, MD, Peter Ganly, BMBCh, PhD, Caroline Dartigeas, MD, András Rosta, MD, PhD, Ann Janssens, MD, Myriam Mendila, MD, Jörg Maurer, Michael K. Wenger, MD

Blood (2008) 112 (11): lba-1.

https://doi.org/10.1182/blood.V112.11.lba-1.lba-1

Published: 2008

Journal Articles

Long-Term Complete Molecular Remissions in Untreated Symptomatic Follicular Lymphoma Treated with Rituximab as Single Agent and in Combination with Interferon-alpha-2a: Analysis of Minimal Residual Disease in the Randomized Phase II Study M39035.

Jesper Jurlander, Christian Geisler, Hans Hagberg, Harald Holte, Tuula Lehtinen, Eva Kimby

Blood (2004) 104 (11): 1393.

https://doi.org/10.1182/blood.V104.11.1393.1393

Published: 2004

NARROW

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

Subset-Specific Spectra of Recurrent Gene Mutations in Chronic Lymphocytic Leukemia with Stereotyped B-Cell Receptors

Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results

Increased Expression Levels Of SOX11 Correlates To Overall Survival and Adds Prognostic Value To The MIPI and MIPI-B Index In a Homogenously Treated Cohort

Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy For Patients >65 Years With Mantle Cell Lymphoma: Preliminary Results From The Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase I-II Trial

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Long-Term Complete Molecular Remissions in Untreated Symptomatic Follicular Lymphoma Treated with Rituximab as Single Agent and in Combination with Interferon-alpha-2a: Analysis of Minimal Residual Disease in the Randomized Phase II Study M39035.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only